Volume 3 Issue 2

Research Article: Monoclonal Antibody Characterization of the Coeliac Toxic Gluten Content of Wheat Starch Standards for a Gluten Test Kit

Ellis HJ, Selvarajah U and Ciclitira PJ*

Coeliac Disease (CD) is treated with a strict Gluten-Free Diet (GFD). Gluten is comprised of gliadin, Low (LMWG) and High (HMWG) Molecular Weight Glutenins. Many commercially available, nominally gluten-free foods are based on purified wheat starch. The only Food and Agriculture Organization of The United Nations (FAO) certified assay for gluten quantitation is based on the R5 monoclonal antibody (MAB) that recognizes gliadin but not glutenin. The R5 estimated gluten content of gluten-free foods involves multiplying the R5 gliadin value by two to yield a gluten value. We have raised a panel of monoclonal antibodies to CD toxic motifs. We assessed the gluten content of three wheat starches A, B, & C that are supplied as standards for the Transia gluten quantitation kit, which is based on a MAB to omega-gliadin. We employed separate ELISAs to quantify gliadin, Low (LMWG) and High Molecular Weight (HMWG) glutenins. Gliadin content in all three starches, as measured by one of the antibodies, was always higher that that measured with the other, but the ratio between measurements made by the 2 MABs varied from 3.1 to 7.0 fold. We also report significant variation in glutenin: gliadin ratios for different wheat starches. We suggest quantitation of the gluten content of nominally gluten-free foods, particularly those based on purified wheat starch, should be determined by measuring gliadin and glutenin, the values for which should be summated, since measurement of gliadin alone, followed by multiplication by two to yield a gluten content, appears to be invalid for processed foods.

Cite this Article: Ellis HJ, Selvarajah U, Ciclitira PJ. Monoclonal Antibody Characterization of the Coeliac Toxic Gluten Content of Wheat Starch Standards for a Gluten Test Kit. Int J Hepatol Gastroenterol. 2017;3(1): 046-049.

Published: 14 September 2017

Mini-Review: Current Insights of Colorectal Cancer: The Anatomical differences and the miRNA Regulation in Colorectal Cancer

Jorge De La Torre, Tyler Billings and Qiongqiong Zhou*

Colorectal cancer is one of the leading causes of death in the United States. Recent advances of understandings in anatomical patterns and molecular mechanisms may bring better therapeutical options and treatment plan. This article reviews the different outcomes of colorectal cancer associated with anatomical pattern: left-sided or right-sided; and the recently discoveries of colorectal cancer related miRNA.

Cite this Article: De La Torre J, Billings T, Zhou Q. Current Insights of Colorectal Cancer: The Anatomical differences and the Mirna Regulation in Colorectal Cancer. Int J Hepatol Gastroenterol. 2017;3(1): 041-045.

Published: 06 September 2017

Case Report: Hepatic Encephalopathy and Foreign Accent Syndrome: a Case Report

Castillo Natalia, Austin Andrew and Freeman Jan George*

Foreign Accent Syndrome (FAS) is a rare phenomenon where speech is characterized by a new accent to the patient's native language. The majority of cases which have been previously described are associated with observed insults of the speech center. Other cases have been related to a psychiatric illness. In this particular case, we present a 62-year-old male with hepatic encephalopathy and FAS. FAS subsequently resolved following the management of Spontaneous Bacterial Peritonitis (SBP).
Keywords: Foreign Accent Syndrome (FAS); Hepatic Encephalopathy; Spontaneous Bacterial Peritonitis (SBP)

Cite this Article: Natalia C, Andrew A, George FJ. Hepatic Encephalopathy and Foreign Accent Syndrome: a Case Report. Int J Hepatol Gastroenterol. 2017;3(1): 038-040

Published: 23 August 2017

Review Article: Hepatorenal Syndrome, Are we making any Progress?

Castillo NE, Rajasekaran A, Austin AS, and Freeman JG*

Hepatorenal Syndrome (HRS) poses a unique challenge to liver failure patients. The key pathophysiologic feature of HRS includes a marked reduction in renal blood flow that is caused by intense vasoconstriction of the renal circulation counteracting the pathologic systemic and splanchnic arterial vasodilation. The diagnosis of HRS requires a reduction in the glomerular filtration rate and exclusion of other causes of renal failure. Novel biomarkers including cystatin C, neutrophil gelatinase associated lipocalin (NGAL), IL-8 and liver-type fatty acid binding protein (L-FABP) have been proven to be useful for predicting HRS. All existing treatments can only be considered supportive. Other potential therapeutic options such as selectively targeting renal vasodilation are promising. Currently, liver transplant is the only treatment that improves long-term survival.
Keywords: Hepatorenal syndrome; Acute kidney injury; Cirrhosis

Cite this Article: Castillo NE, Rajasekaran A, Austin AS, Freeman JG. Hepatorenal Syndrome, Are we making any Progress? Int J Hepatol Gastroenterol. 2017;3(1): 028-037.

Published: 23 August 2017

Submit ManuscriptSubmit Special Issue

Authors submit all Proposals and manuscripts via Electronic Form!

All Journals

Creative Commons License Open Access by SciRes Literature is licensed under a Creative Commons Attribution 4.0 International License. Based on a work at www.scireslit.com.